AI protein design company Profluent closed a $106 million financing led by Altimeter Capital and Bezos Expeditions to expand large‑scale models for protein design and commercialize bespoke proteins across therapeutics, agriculture and biomanufacturing. Profluent says its Protein Atlas contains over 115 billion proteins and that partners are already deploying its models for enzymes, antibodies and other biologics. Profluent will use the funds to scale compute, broaden R&D and expand commercial partnerships (including recent collaborations with Integrated DNA Technologies and Revvity). The round underscores continued investor appetite for AI‑first platforms that promise to accelerate protein engineering and highlights strategic interest from deep‑pocket backers preparing for industrial and therapeutic applications.